[ad_1]
Jan Haudemann-Andersen has hit the nail on the head at Kahoot! and the vaccine company Vaccibody og trousers on the list of the richest people in Norway.
The online newspaper wrote in October that vaccine technology company Vaccibody had struck a deal worth up to NOK 6.7 billion with US giant Genentech. Vaccibody develops cancer vaccines with immunotherapy and was listed on the Oslo Stock Exchange in October 2020, now the new Euronext Growth exchange.
The deal and faith in the company have led to a completely insane ride in the stock market (see chart below). The market value of the vaccine company is now NOK 25.3 billion.
– We think this is incredibly exciting. And the deal they have received is the largest deal of its kind in Norway, analyst Lars Mørland Knudsen at Arctic Securities said last fall of the big deal. The stock market clearly thinks the same.
Also read: Gjelsten and Hagen are great owners: hope for a cancer vaccine sends cattle to heaven
Vaccine for COVID-19
But since April 2020, Vaccibody has also been working intensively on a coronary vaccine that they believe will provide faster and better protection against the virus.
– Our Cov2 vaccine is now in the preclinical phase, which arrives immediately before the first clinical trials. It is still too early to comment on the next step and further course before we have full data material and have a dialogue with authorities, says CEO Michael Engsig at Vaccibody to Nettavisen
– But preliminary results from animal studies in the preclinical phase have been encouraging. We see possible signs of a fast and strong high, as well as a long-term effect, he continues.
Great victory
The one who has really hit the mark with the investment in Vaccibody is the billionaire and investor Jan Haudemann-Andersen. Through his investment firm Datum, he is a major shareholder in the company. In no time, he received a paper profit of more than 800 million crowns.
Finansavisen wrote in October 2019 that Haudemann-Andersen moved into the company as early as 2014. At the time, the price of a share increase was low at NOK 3, which earned the company a modest NOK 42 million. The share price is now almost NOK 90, the value of the company just over 500 times higher.
Through his company Datum AS, Jan Haudemann-Andersen owns 8.8 per cent of the shares. This means that in today’s market you are sitting on Vaccibody securities for just under NOK 2.3 billion and over NOK 2 billion in paper earnings.
The other large Vaccibody owners are the Rasmussen Group with 8.5%, the Radforsk investment foundation (cancer research) with 8% and the Andenæs family with 4%. These have values of NOK 1-2 billion. It is emphasized that these billions are on paper.
Also read: Norwegian vaccine to be tested in a new study: it can give hope to cancer patients
Two vaccines
Then-PhD student Agnete Fredriksen and Supervisor Bjarne Bogen and her fellow professor Inger Sandlie founded Vaccibody in 2007.
The company currently has two vaccines in so-called clinical development. VB10. NEO is an individualized cancer vaccine and VB10.16 is a cancer vaccine targeting cancers caused by HPV 16.
HPV stands for Human Papillomavirus and it has been shown to be important for the development of cervical cancer.
– Both vaccines are in the clinical examination phase, which is known as phase 2. In this phase, product candidates test on patients to assess effect and safety, Engsig says.
It says that Vaccibody is one of the so-called vaccine technology companies within the biotech platform. All products and all future research focus are based on what Engsig describes as “unique and patented vaccine technology.”
Also read: Advances in cancer research: – A new form of immunotherapy can possibly treat many types of cancer
Great potential
– It also means that Vaccibody’s potential extends well beyond the projects we currently have in clinical development, Engsig says.
– What can you say about the agreement with Genentech?
– For us, Genentech is a “partner of choice”. Our agreement with Genentech is clearly validating our technology to the outside world. At the same time, the agreement places our product candidate VB10. NEO in the best hands.
– In addition, the agreement gives us the financial muscle to realize our vision of becoming the company within the global vaccine technology, responds Danish Engsig.
No rotation
As Vaccibody is in a development phase, the company is far from generating income. Turnover is minimal and the deficit after nine months last year was NOK 137 million. Engsig says it is too early to say whether they can wait for approval.
– It depends above all on our upcoming constructive dialogues with the health authorities, who will lead the way in which the next phases of clinical development will be facilitated.
– When do you expect to earn money?
– With the Genentech agreement, we have secured a solid financial foundation for further Vaccibody growth. This means that we do not have a concrete need for capital here and now. At the same time, we are a very ambitious company with great potential and with great visions, which naturally require capital in the long run.
– When we have presented our future plans, we will update the stock market on our detailed research and development strategy and on our additional capital market strategy, Engsig responds.
Also Read: Famous Investors Get Super Profits at Kahoot!
Solid
But the company is strong, with an equity ratio of up to 87 percent. Vaccibody’s market value is roughly 150 times higher than the company’s equity, but it’s the growth prospects that are key.
Jan Haudemann-Andersen has really hit the mark with his investments in Vaccibody and the Kahoot game company! The latter has a staggering price tag of 54 billion. The action of Kahoot! It fell sharply on Wednesday after a fourth-quarter pre-tax loss of $ 28.7 million, NOK 242 million.
Although it has slowed down a bit lately, the stock price has risen a little over 450 percent in no time (see chart below). According to the annual report, Haudemann-Andersen owns 11.7 percent of Kahoot. Through its investment company Date, 52.13 million shares. That gives you Kahoot values! For 6,300 million.
No sales plans
Total Haudemann-Andersen values in Kahoot! and Vaccibody today, at 8.5 billion, would have brought him closer to the top 20 list according to Kapital magazine’s ranking of the 400 richest people in Norway.
Last fall, Kapital Haudemann-Andersen was ranked 49th among the richest in Norway, with an estimated total wealth of NOK 4.9 billion.
Jan Haudemann-Andersen will not tell Nettavisen anything about how he sees the investment in Vaccibody. He told Finansavisen in October that he had no plans to sell Vaccibody or Kahoot!
Advertising
This book may be the most beautiful piece of furniture in the house.
